Pharmaceutical Giant GSK Reaches Major Settlement
British pharmaceutical company GSK has agreed to pay $2.3 billion to settle lawsuits alleging that its heart burn medication Zantac caused cancer. GSK has settled 80,000 Zantac lawsuit. Watch to know ...
Roche/Genentech’s Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results
While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a serious complication of systemic lupus ...
UK stocks drag as investors cautious despite US inflation slowing
London’s FTSE 100 was down 6.01 points, or 0.07%, to close at 8,237.73, with housebuilders among the stocks dragging on the ...
GSK resolves Zantac cancer claims with a £1.7 billion settlement, boosting shares
The pharmaceutical giant has agreed to a $2.2bn (£1.68bn) settlement to resolve lawsuits in the US alleging that the ...
Inverness Courier3d
GSK shares jump after landmark £1.68bn heartburn drug settlement
The pharmaceutical giant has settled the vast majority of cases around its drug Zantac in the US, boosting investor ...
GSK shares jump on $2.2 billion Zantac settlement
GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits ...
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...
TMCnet5d
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK's proprietary AS01E adjuvant.
standard-journal6d
ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries
Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare and President, Global Health at GSK, said: “Today’s announcement marks another important milestone in our efforts to accelerate access to ...